Early activation of p38 mitogen activated protein kinase is associated with interferon-alpha-induced depression and fatigue

Brain Behav Immun. 2011 Aug;25(6):1094-8. doi: 10.1016/j.bbi.2011.02.015. Epub 2011 Feb 26.

Abstract

Cytokine-induced stimulation of p38 mitogen activated protein kinase (MAPK) has been shown to influence behaviorally-relevant pathophysiologic pathways including monoamine neurotransmission and neuroendocrine function and thus may contribute to behavioral changes that occur during chronic administration of the innate immune cytokine, interferon (IFN)-alpha. Accordingly, in the current study, phosphorylation (activation) of intracellular p38 MAPK in peripheral blood lymphocytes was analyzed by flow cytometry every 2 h for 12 h following the initial injection of IFN-alpha in eleven patients with chronic hepatitis C. Hourly assessments of plasma concentrations of adrenocorticotropic hormone, cortisol and interleukin-6 were also obtained. Symptoms of depression and fatigue were measured at baseline and after 4 and 12 weeks of IFN-alpha treatment. Acute administration of IFN-alpha significantly increased the percentage of lymphocytes staining positive for intracellular phosphorylated p38 (p-p38). IFN-alpha-induced increases in p-p38 were significantly greater in patients that developed clinically significant depressive symptoms [Montgomery-Asberg Depression Rating Scale (MADRS) score≥15] during the first 12 weeks of IFN-alpha treatment. Increases in the percentage of p-p38-positive lymphocytes following the first IFN-alpha injection also highly correlated with depression severity at weeks 4 (r=0.85, p=0.001) and 12 (r=0.70, p=0.018). Similar relationships were observed for fatigue. Examination of relationships between p-p38 induction and factors previously reported to predict IFN-alpha-induced depressive symptoms revealed strong associations of p-p38 with baseline MADRS (r=0.82, p=0.002) and cortisol responses to the initial injection of IFN-alpha (r=0.91, p=0.000). Taken together, these findings indicate that sensitivity of p38 MAPK signaling pathways to immune stimulation is associated with depressive symptoms during chronic IFN-alpha treatment.

Publication types

  • Clinical Trial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiviral Agents / pharmacology
  • Antiviral Agents / therapeutic use
  • Depression / chemically induced*
  • Depression / enzymology
  • Drug Therapy, Combination
  • Fatigue / chemically induced*
  • Fatigue / enzymology
  • Hepatitis C, Chronic / drug therapy
  • Humans
  • Hydrocortisone / blood
  • Hydrocortisone / metabolism
  • Immunity, Innate
  • Interferon alpha-2
  • Interferon-alpha / administration & dosage
  • Interferon-alpha / pharmacology*
  • Interferon-alpha / therapeutic use
  • Interleukin-6 / blood
  • Lymphocytes / drug effects*
  • Lymphocytes / metabolism
  • Phosphorylation / drug effects
  • Polyethylene Glycols / administration & dosage
  • Polyethylene Glycols / pharmacology*
  • Polyethylene Glycols / therapeutic use
  • Protein Processing, Post-Translational / drug effects
  • Recombinant Proteins / administration & dosage
  • Recombinant Proteins / pharmacology
  • Recombinant Proteins / therapeutic use
  • Ribavirin / administration & dosage
  • Ribavirin / therapeutic use
  • Severity of Illness Index
  • Time Factors
  • p38 Mitogen-Activated Protein Kinases / genetics
  • p38 Mitogen-Activated Protein Kinases / metabolism*

Substances

  • Antiviral Agents
  • IL6 protein, human
  • Interferon alpha-2
  • Interferon-alpha
  • Interleukin-6
  • Recombinant Proteins
  • Polyethylene Glycols
  • Ribavirin
  • p38 Mitogen-Activated Protein Kinases
  • peginterferon alfa-2b
  • peginterferon alfa-2a
  • Hydrocortisone